What the FDA labels say about taking them together
Dexamethasone and thalidomide
Dexamethasone's FDA label of June 6, 2025 names thalidomide in its drug interactions section, and thalidomide's label names dexamethasone too. The dexamethasone label: “Closely monitor for toxicity when thalidomide is coadministered with HEMADY.”
Check it at the source: the dexamethasone FDA label on DailyMed (effective June 6, 2025, Hikma Pharmaceuticals USA, Inc.); the thalidomide FDA label on DailyMed (effective March 24, 2023, Celgene Corporation).
What does the dexamethasone label say about thalidomide?
Dexamethasone label, drug interactionsCo-administration with thalidomide should be employed cautiously, as toxic epidermal necrolysis has been reported with concomitant use.
Hemady label (Edenbridge Pharmaceuticals LLC., January 9, 2026), drug interactionsClosely monitor for toxicity when thalidomide is coadministered with HEMADY.
Hemady label (Edenbridge Pharmaceuticals LLC., January 9, 2026), warnings and precautionsThe risk for venous and arterial thromboembolism increases significantly when dexamethasone is administered with anti-myeloma products (e.g., thalidomide, lenalidomide, pomalidomide, and carfilzomib).
Source: FDA drug label (Hemady, NDA211379), Edenbridge Pharmaceuticals LLC., effective January 9, 2026 (SPL set 6b9cf32c-6d60-4853-bbfd-2304ffc2c129), via openFDA
Source: FDA drug label (Dexamethasone Intensol), Hikma Pharmaceuticals USA, Inc., effective June 6, 2025 (SPL set b15200fb-1826-472b-a907-e677a272513b), via openFDA; the full label on DailyMed
What does the thalidomide label say about dexamethasone?
Thalidomide label, boxed warningSignificant increased risk of deep vein thrombosis (DVT) and pulmonary embolism (PE) in patients with multiple myeloma receiving THALOMID with dexamethasone ( 5.3 ).
Thalidomide label, drug interactionsTherapies that may Increase the Risk of Thromboembolism Erythropoietic agents, or other agents that may increase the risk of thromboembolism, such as estrogen containing therapies, should be used with caution in multiple myeloma patients receiving THALOMID with dexamethasone [see Warnings and Precautions (5.3) ].
Thalidomide label, warnings and precautionsIncreased Mortality: Observed in patients with MM when pembrolizumab was added to dexamethasone and a thalidomide analogue.
Source: FDA drug label (Thalomid), NDA020785 (Bristol-Myers), as published by Celgene Corporation, effective March 24, 2023 (SPL set 2eda833b-1357-4ed4-a093-194524fcb061), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Dexamethasone | Thalidomide | |
|---|---|---|
| Labeled for | Asthma, Eczema (atopic dermatitis), Leukemia, lymphoma and myeloma, Herpes and shingles, Crohn's disease and ulcerative colitis, Multiple sclerosis, Osteoarthritis, Rheumatoid arthritis, Psoriasis, Allergies, Anemia, Pain | Leukemia, lymphoma and myeloma |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | $0.193 per tablet 4 mg tablet | n/a |
| Shortage now | In shortage | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once